Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide PK and Safety in Healthy Chinese Volunteers
NCT03887221Phase 1Completed
- Sponsor
- Zambon
- Start
- Jun 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of safinamide in Parkinson's disease (PD) (2 arms), sponsored by Zambon. Primary endpoints: Maximum Plasma Concentration at Day 8, Time to Maximum Concentration at Day 8 and 6 more. Started Jun 2021; status: completed.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03887221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03887221.